S Quddusi, TP Vahl, K Hanson, RL Prigeon, DA … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Nine diabetic subjects and nine nondiabetic
volunteers of similar age and weight were studied in identical protocols.
First-phase insulin release (FPIR; the incremental insulin response in the ... Cited by 51 - Related articles - BL Direct - All 5 versions
- ►endojournals.org MB Toft-Nielsen, S Madsbad, JJ Holst - Journal of Clinical Endocrinology & Metabolism, 2001 - Endocrine Soc GLP-1 lowers blood glucose in fasting type 2 diabetic patients. To clarify the
relation of the effect of GLP-1 to obesity, blood glucose, ß-cell function, and
insulin sensitivity, GLP-1 (1.2 pmol/kg·min) was infused iv for 4–6 h ... Cited by 45 - Related articles - BL Direct - All 6 versions
J Rachman, FM Gribble, BA Barrow, JC Levy … - Diabetes, 1996 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is a natural enteric incretin hormone, which is
a potent insulin secretogogue in vitro and in vivo in humans. Its effects on
overnight glucose concentrations and the specific phases of insulin ... Cited by 87 - Related articles - BL Direct - All 4 versions
- ►critcaremed.com JJ Meier, D Weyhe, M Michaely, M Senkal, V … - Critical care medicine, 2004 - journals.lww.com From the Department of Medicine I, St. Josef-Hospital, Ruhr-University Bochum,
Germany (JJM, WES, BG); the Department of Surgery, St. Josef-Hospital,
Ruhr-University Bochum, Germany (DW, MM, MS, VZ); Diabeteszentrum Bad ... Cited by 26 - Related articles - BL Direct - All 9 versions
- ►diabetesjournals.org B Elbrønd, G Jakobsen, S Larsen, H Agersø, … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a double-blind, randomized dose, escalation,
placebo-controlled study, healthy male subjects were enrolled at eight
consecutive dose levels (1.25, 2.5, 5.0, 10.0, 12.5, 15.0, 17.5, and 20.0 ... Cited by 103 - Related articles - BL Direct - All 6 versions
[CITATION] Abnormal glucagon secretion in type 2 (noninsulindependent) diabetes mellitus: causes …
- ►diabetesjournals.org R Ritzel, M Schulte, N Pørksen, MS Nauck, … - Diabetes, 2001 - Am Diabetes Assoc The insulinotropic gut hormone glucagon-like peptide (GLP)-1 increases secretory
burst mass and the amplitude of pulsatile insulin secretion in healthy
volunteers without affecting burst frequency. Effects of GLP-1 on secretory ... Cited by 42 - Related articles - BL Direct - All 4 versions
- ►endojournals.org TP Vahl, BW Paty, BD Fuller, RL Prigeon, DA … - Journal of Clinical Endocrinology & Metabolism, 2003 - Endocrine Soc Glucagon-like peptide 1 (GLP-1) is an insulin secretagogue synthesized in the
intestine and released in response to meal ingestion. It is secreted primarily
in two forms, GLP-1-(7–37) and GLP-1-(7–36)NH 2 , both of which bind to ... Cited by 56 - Related articles - BL Direct - All 6 versions
R Burcelin, A Da Costa, D Drucker, B Thorens - Diabetes, 2001 - Am Diabetes Assoc Activation of the hepatoportal glucose sensors by portal glucose infusion leads
to increased glucose clearance and induction of hypoglycemia. Here, we
investigated whether glucagon-like peptide-1 (GLP-1) could modulate the ... Cited by 127 - Related articles - BL Direct - All 8 versions
[CITATION] Vildagliptin added to metformin improves glycemic control and may mitigate metformin- …
